Ann: NYR Secures Collaboration with Walter Reed and UNSW, page-40

This company poses as one of the most exciting companies on the ASX - and with the pre-clinical results looking positive this could be a game changer in the management of high cholesterol (low density lipoprotein - LDL) reducing the prevalence of ischemic heart disease leading to heart attacks or strokes. They are not trying to overtake Statins (widely regarded as the gold standard med for prevention, diet and exercise aside) but work in conjunction to increase the efficacy of the treatment. Should the human trials deliver positive results for this medication - you are essentially and literally changing the game for those where Statins have no affect.

Then there is the first ever pharmaceutical treatment for secondary brain injury. The treatment wants to increase survivability but also reduce disability. The market opportunity (unfortunately) is also extensive with motor vehicle accidents, assaults/trauma, hypoxia (lack of oxygen to tissue and cells) and potentially chronic traumatic encephalopathy (CTE), the latter is my own speculation but an increasingly more prevalent condition.

Exciting Business here ladies and gents - free float must be tiny now, so any positive news will see this move quickly. GLTAH